Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Treatment regimen

Darolutamide with docetaxel and hormone therapy (ARASENS)

Triplet therapy in metastatic hormone-sensitive prostate cancer

Updated: 28 October 20261 min read3 references

Summary for doctors

  • Metastatic hormone-sensitive prostate cancer, especially high-volume disease [1].
  • Adding darolutamide to docetaxel and ADT lowered the risk of death by about 32% [1].

Dose and schedule

ARASENS

Metastatic hormone-sensitive prostate cancer

Metastatic hormone-sensitive prostate cancer

DrugDoseRouteSchedule
Hormone therapy (ADT)GnRH agonist or antagonist, or surgical castrationContinuous
Darolutamide600 mg twice a dayOral, with foodDaily
6 cycles
Docetaxel75 mg/m²IVEvery 21 days
Cycle length
Darolutamide daily; docetaxel every 21 days
Duration
Darolutamide and ADT until progression; docetaxel 6 cycles

As in ARASENS [1]; docetaxel within 6 weeks of starting ADT [1].

Dose source: [3].

Evidence: ARASENS (2022)

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Premedication and supportive care

  • Docetaxel premedication; G-CSF in older patients; bone health (calcium, vitamin D, bone density).

Monitoring and dose adjustment

  • PSA, blood counts and liver enzymes; darolutamide has fewer drug interactions than other hormonal tablets.

Main evidence

Show detailsHide

ARASENS: 4-year survival 62.7% with darolutamide vs 50.4% with placebo, both with docetaxel and ADT [1]. CHAARTED: docetaxel with ADT in high-volume disease [2].

Related cancer types

Prostate cancer

Treatment regimens (physicians)

Docetaxel in metastatic prostate cancer

Physician tools and lessons

Localised Prostate Cancer Risk Group Calculator10 cheap steps that save patients' livesBone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jawGermline genetic testing in cancer: who, and which genes?

References

3 references
Show all references, 2 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerSmith MR, Hussain M, Saad F, et al · N Engl J Med · 2022;386:1132-1142
    Study cardDOIPubMed Back to text: 1 2 3 4 5
  2. 2
    Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerSweeney CJ, Chen YH, Carducci M, et al · N Engl J Med · 2015;373:737-46
    Study cardDOIPubMed Back to text
  3. 3
    NUBEQA (DAROLUTAMIDE) — Prescribing InformationBayer Healthcare Pharmaceuticals Inc · FDA label · 2026
    Source Back to text

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/darolutamide-docetaxel-adt/

Related pages

27 October 2026 FOLFOX (mFOLFOX6): dose, schedule and side effects Dose and schedule of mFOLFOX6 (oxaliplatin 85, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), length of adjuvant treatment, premedication, neuropathy and dose adjustment. 27 October 2026 CAPOX (XELOX): dose, schedule and side effects Dose and schedule of CAPOX or XELOX (oxaliplatin 130 and capecitabine 1000 twice daily, days 1 to 14), length of adjuvant treatment, renal adjustment and side effects. 27 October 2026 FOLFIRI regimen: dose, schedule and side effects Dose and schedule of FOLFIRI (irinotecan 180, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), diarrhoea control, UGT1A1 and dose adjustment.